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ABSTRACT
Space motion sickness is an important issue in the space medical
sciences program. Although scopolamine has been documented to be
an effective antimotion sickness agent, limited information is
available regarding the pharmacodynamics of scopolamine and the
relationship between the pharmacodynamics and the
pharmacokinetics of the drug. One of the objectives of the
ongoing clinical experimental protocol "Pharmacokinetics of
Intranasal Scopolamine in Normal Subjects" is to evaluate the
pharmacodynamics of scopolamine using salivary flow rate and pH
profiles and cognitive performance tests as pharmacodynamic
parameters.
Normal volunteers collected saliva and performed the NTI
Multiresource Performance Battery test at designated time
intervals to establish control salivary flow rates, salivary pH
profiles, and the characteristics of the learning curve for the
performance program under normal conditions. Salivary flow
ranged between 50 to 60 ml/hr with pH ranging between 6.5 to 7
over a 2 hour period. Preliminary assessment of the performance
data from the first few volunteers suggests that the duration of
the learning curve is short reaching a plateau after two test
sessions for task one and five to eight test sessions for task
two.
In the clinical part of the study, saliva samples and performance
test scores are collected from healthy nonsmoking subjects after
receiving a single 0.4 mg dose of either intranasal, intravenous,
or oral scopolamine. Both salivary flow rate and pH decreased as
a function of time after administration of all the three dosage
forms. The pharmacodynamic effect as indicated by salivary flow
rate and pH was the greatest after intravenous administration and
the least after oral administration. Preliminary analysis of the
performance parameters for a limited number of subjects indicates
that there is no significant change in task one or task two
scores following the administration of any of the three dosage
forms. However, the mean correct response times for tasks
following the transition from one task to another appear to be
slightly longer during the first few hours following scopolamine
administration.
Preliminary evaluation of this limited data suggests that
salivary flow rate and pH are good pharmacodynamic indicators for
scopolamine, and that intranasal scopolamine produces a reliable
and consistant pharmacodynamic effect. Limited performance data
collected so far suggest that scopolamine does not decrease
cognitive function as measured with the NTI Multiresource
Performance Battery. Results from the study may be useful in
identifying and selecting effective dosage forms for the
management of SMS.
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INTRODUCTION
Space motion sickness (SMS) is a major concern in the space
medical sciences program. Approximately 50-60% of astronauts
experience SMS, which usually affects astronauts during the first
three days of flight and may be severe enough to compromise the
operational performance of the astronaut (i). Use of antimotion
sickness drugs in flight has been limited by drug ineffectiveness
or by undesirable side effects that impair the operational
performance of the astronaut. Scopolamine, an anticholinergic
drug, has been documented to be an effective antimotion sickness
agent (2,3). It has been suggested that scopolamine interupts
the acetylcholine-dependent neurotransmission of information from
the vestibular organs to the vomiting centers of the brainstem
(4,5). At present, scopolamine (0.4 mg) in combination with
dextroamphetamine (5 mg) is administered orally as a capsule for
the prophylaxis and treatment of SMS. An important side effect
of operational significance induced by scopolamine is the
impairment of cognitive performance. Another side effect that is
not of clinical importance but can be used as a pharmacodynamic
indicator is inhibition of salivary secretion.
Although a veteran drug, the pharmacodynamics of scopolamine and
the relationship between the pharmacokinetics and the
pharmacodynamics of the drug have not been well characterized.
Several investigators have documented that oral scopolamine
impairs cognitive performance; the techniques used are complex
and time-consuming (6-12). Identification of a sensitive and
convenient method for the assessment of drug-induced performance
changes would be helpful in establishing the selection criteria
for drugs used for the prophylaxis and treatment of SMS and also
for the pharmacodynamic assessment of these drugs during space
flight. The project therefore was designed to l) establish
salivary parameters in control subjects using the Sarstedt
Salivette system, 2) to determine cognitive performance in
control subjects using the NTI Multiresource Performance Battery,
and 3) to compare the effect of a 0.4 mg dose of intranasal,
intravenous, and oral scopolamine on these parameters.
MATERIALS AND METHODS
Scopolamine Study
A conventional clinial IND protocol was designed to evaluate the
pharmacokinetics and bioavailability of the three dosage forms.
Healthy nonsmoking male subjects ranging between 18 to 40 years
of age are participating in the study. All subjects passed an
Air Force Class III physical examination, including hematology,
electrocardiogram, urinalysis, and biochemistry tests before
admission to the study. The study protocol was approved by the
human research review committees of NASA-JSC and the St. John
Hospital. Informed consent was obtained from all the subjects
prior to the study.
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The study consists of an intranasal, an intravenous, and an oral
treatment phase. A 0.4 mg dose is used in all three treatment
phases. Each 24 hour treatment phase is separated by at least a
two week period. The treatments are administered in a
predetermined randomized crossover design. Oral scopolamine was
customed manufactured by AC Engle & Co, Houston, Texas,
intravenous scopolamine dosage form was procured from a pharmacy,
and intranasal scopolamine was customed-manufactured by the
Pharmaceutics Department of the University of Houston, Houston,
Texas. Subjects are admitted to the hospital the night before
each study period. Each subject is given written and oral
instructions for the Multiresource Performance Battery computer
program and trained until they are comfortable with the computer
keyboard and the program. Mixed saliva is collected over a two
minute interval using the Sarstedt Salivette system (a cotton
swab collection system) before and at 5, i0, 15, 20, 30, 45, 60,
90 minutes and 2, 3, 4, 5, 6, 8, i0, and 12 hours after dosing.
The Multiresource Performance Battery test is taken pre-dose and
at i, 2, 3, 4, 5, 6, 8, i0, and 12 hours post-dose.
The investigational Multiresource Performance Battery computer
program was obtained from NTI, Inc. The program runs on a
portable personal computer and is designed to test the higher
cognitive functions most likely to be affected by centrally
active drugs. The program consists of two timed tasks presented
pseudosimultaneously with an attention allocation indicator.
Both tasks appear on the screen simultaneously with two bars of
differing height at the bottom center of the screen. The active
task is identified as the task on the side of the screen with the
highest bar. The math task appears on the left of the screen and
consists of a two step (addition, subtraction, or combination)
single digit math problem. The key "z" is pressed if the answer
is less than five and the key "v" is pressed if the answer is
greater than five. The memory task appears on the right of the
screen and consists of two single digit numbers separated by a
line. The task is to determine if the numerator of the current
active task matches the denominator of the prior active task.
The key "m" is pressed if the numbers match and the key "/" is
pressed if the numbers do not match. The test battery consists
of i00 randomly generated tasks with an approximately equal
distribution between the two tasks. Each I00 task test battery
is preceded by a randomly generated 20 task warm-up battery that
may be repeated until the subject no longer feels his performance
is improving. The program allows for a maximum of five seconds
for a response before randomly changing to a new test in the same
task or to the alternate task. Performance parameters include
the percent correct, incorrect and timed out and the mean correct
response times for both tasks as well as the percent correct,
incorrect, and timed out and the mean correct response times for
the transitions to each task and for the total transitions.
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Control Data Collection
Because the NTI Multiresource Performance Battery is a new
investigational program, no data exists on the learning curve
with the program. Preliminary analysis of data from the first
few subjects suggested a learning curve interval which may mask
the drug effect. Another contributing factor of variability may
be the time of day (i.e. morning vs. afternoon). To address
these issues, ten normal volunteers were selected for twice daily
testing for ten days. Each subject received verbal and written
instructions for the Multiresource Performance Battery and was
then tested twice daily (in the morning and afternoon) for a
total of 20 tests over a three week period. The performance
parameters (percent correct, incorrect and timed out; mean
correct response times; and transition percents and response
times) for each task will be analyzed and the learning curve will
be characterized.
To evaluate whether the repeated collection of saliva with the
Salivette system during the first hour of the study would alter
salivary flow dynamics, four volunteers repeated the saliva
sampling protocol for the clinical study. Salivary volume and pH
were measured and flow rate calculated for each time period.
PRELIMINARY RESULTS
Control Data
Sallvary Data. Sample collection and data analysis for the
salivary data was completed. Salivary flow rate and pH appears
to be relatively constant over the twelve hour sampling period
using the Salivette system (Figure 1). Mean flow rate ranged
between 50 to 60 ml/hr and mean salivary pH ranged between 6.5
and 7.0. No significant changes in flow rate or pH were noticed
as a function of either the frequency of samples or time of day.
Performance Data. Data collection for this parameter is still in
progress. Preliminary assessment of the data from the first few
trials suggests that there is a subject dependent learning
pattern with the program. In some individuals there was no
improvement which suggests that these subjects did not exhibit a
learning curve, but in others there was an apparent learning
curve. There was a considerable intersubject variability in
scores, but plateau scores were relatively constant for each
individual. The learning curve appears to plateau after two test
sessions with the math task and after five to eight test sessions
with the memory task. There does not appear to be any difference
between scores achieved in the morning versus scores achieved in
the afternoon.
Scopolamine Study
Salivary Data. A limited number of subjects (intranasal n=8;
intravenous n=7; oral n=8) have completed the study so far.
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Preliminary results from these subjects were evaluated and
reported here. Although all three dosage forms of scopolamine
appear to decrease salivary flow rate and salivary pH,
differences are apparent between the dosage forms (Figure 2).
Intravenous scopolamine markedly inhibited salivary flow rate and
lowered salivary pH. Flow was nearly totally inhibited in the
first 15 minutes following administration of the drug, with a
slow recovery to pre-dose flow in four to six hours. Salivary pH
fell from the pre-dose mean of 6.6 to 5 in the first 90 minutes
following intravenous administration of the drug, with slow
recovery to pre-dose value by five hours. Intranasal scopolamine
lowered salivary flow to about 5 ml/hr in about one hour with a
slow recovery at nearly the same rate as with intravenous
scopolamine. Salivary pH fell from the pre-dose mean of 6.7 to
4.8 in the first 90 minutes following the intranasal
administration of the drug, which was a slightly larger decline
than with the intravenous dosage form. Oral scopolamine caused a
small decrease in flow in about one hour, with recovery to pre-
dose flow by two hours. Salivary pH fell slightly from the pre-
dose mean of 6.7 to 6.3 in the first three hours following oral
administration.
Performance Data. Preliminary analysis of the performance
parameters for the first few trials suggests that there is no
change in task one or task two scores (percent correct, percent
incorrect, percent timed out) following the administration of
intranasal, intravenous, or oral scopolamine. None of the three
dosage formulations adversely affected the mean correct response
times for task one or task two. However, the mean correct
response times for performance of task one following transition
from task two and for performance of task two following
transition from task one appear to be slightly longer in the
first few hours following drug administration (Figure 3).
DISCUSSION
The flow rate of mixed saliva following the administration of
anticholinergic drugs has been reported but was not well
characterized. Grundhofer and Gibaldi found that oral
administration of the anticholinergic drugs propantheline and
hexocyclium lowered salivary flow rate by approximately 75% in
two hours, with a gradual recovery to pre-dose rate by four to
six hours (13,14). Brand et al reported that the administration
of scopolamine at oral doses of 0.42 and 0.7 mg lowered salivary
flow rate to approximately 50% of baseline by two to three hours
(15). Gordon et al found that transdermal scopolamlne lowered
salivary flow rate by about 50% after 12 to 18 hours of
transdermal administration (16). The present investigation is
the first of its kind to utilize salivary characteristics for
pharmacodynamic evaluation of dosage forms of scopolamine.
Limited data collected so far indicate that there are differences
in the pharmacodynamic effect as suggested by salivary flow rate
after intranasal, intravenous, and oral administration of
scopolamine, with a fast and pronounced effect from the
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intravenous dosage form and a relatively slow and minimal effect
from the oral dosage form. This appears to reflect the
differences in pharmacokinetics and bioavailability of the three
dosage forms.
Salivary pH depends on salivary flow (17). Therefore, it is
anticipated that salivary pH decreased with the decreased flow
rate. However, the lowest mean salivary pH following the
intravenous and intranasal administration of scopolamine is lower
than the 5.8 reported by Kreusser for unstimulated salivary
glands. Salivary pH appears to be a good indicator of the
differences in pharmacodynamic effect of different dosage forms,
which may be a function of the pharmacokinetic properties of the
three dosage forms.
Although psychometric testing has been used to assess the
pharmacodynamic effects and side effects of centrally active
drugs, limited information is available regarding the shapes and
duration of learning curves or their interference in repeated
measures testing. Schulz suggested that subjects should be given
a period of familiarization with the testing procedures followed
by repeated testing until the subjects achieve a predetermined
coeffiecient of variation (18). Our results suggest that there
is a learning curve with both tasks in our study, and that
although there is some intersubject variability in individual
plateaus for efficiency, the subjects require several tests to
reach peak efficiency with the memory task. This data suggests
that subjects require more experience with the program than is
currently being provided prior to testing after administration of
the drug.
Traditional psychometric testing has documented that oral
scopolamine impairs cognitive performance (6-12). Acetylcholine
appears to be important for the processes of sustained attention
and vigilance (7,19,20) as well as stimulus processing and
memory storage (21-26). Although early studies indicated that
scopolamine impaired longterm recall (23,27), more recent studies
indicate that scopolamine impairs tasks involving sustained
continuous attention or the storage of new information into
memory rather than recall of information memorized before drug
administration (8,11,12). In an investigation using a different
investigational NTI performance battery, it was reported that
scopolamine did not affect performance when using reaction time
as a parameter for either spatial or verbal resources, but that
scopolamine did impair the attention allocation system (28).
Although preliminary, present data appear to support the findings
that scopolamine impairs tasks requiring sustained continuous
attention and processing of newly memorized information.
CONCLUSION
Limited information regarding the pharmacodynamics of scopolamine
has been reported. This study was designed to quantitate the
differences in pharmacodynamics between the intranasal,
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intravenous, and oral dosage formulations of scopolamine. Data
analysis for the completed studies will be performed and the
relationship between the pharmacodynamics and the
pharmacokinetics of the drug will be determined. It is
anticipated that the results from these studies will provide new
information that will be useful in the selection of appropriate
drugs and dosage forms for the management of space motion
sickness.
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